BR112018011552A2 - métodos e composições para tratamento de úlceras gástricas - Google Patents

métodos e composições para tratamento de úlceras gástricas

Info

Publication number
BR112018011552A2
BR112018011552A2 BR112018011552A BR112018011552A BR112018011552A2 BR 112018011552 A2 BR112018011552 A2 BR 112018011552A2 BR 112018011552 A BR112018011552 A BR 112018011552A BR 112018011552 A BR112018011552 A BR 112018011552A BR 112018011552 A2 BR112018011552 A2 BR 112018011552A2
Authority
BR
Brazil
Prior art keywords
gastric ulcers
compositions
methods
treating gastric
composition
Prior art date
Application number
BR112018011552A
Other languages
English (en)
Other versions
BR112018011552B1 (pt
Inventor
Bova Nicholas
Garg Sanjay
Page Stephen
Original Assignee
Luoda Pharma Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2015905078A external-priority patent/AU2015905078A0/en
Application filed by Luoda Pharma Pty Ltd filed Critical Luoda Pharma Pty Ltd
Publication of BR112018011552A2 publication Critical patent/BR112018011552A2/pt
Publication of BR112018011552B1 publication Critical patent/BR112018011552B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

um método de tratamento e/ou prevenção de úlceras gástricas, com o referido método compreendendo a administração, por injeção, de uma quantidade terapeuticamente eficaz de uma composição compreendendo: c) um primeiro agente selecionado do grupo consistindo em: um triglicerídeo de cadeia média e um triglicerídeo de cadeia longa; e d) um segundo agente compreendendo um inibidor da bomba de prótons ou um sal farmacêutica ou veterinariamente aceitável, em que a composição é adaptada para liberação prolongada de uma quantidade terapeuticamente eficaz do inibidor da bomba de prótons a um sujeito em necessidade.
BR112018011552-5A 2015-12-08 2016-12-08 Composições para tratamento de úlceras gástricas BR112018011552B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2015905078 2015-12-08
AU2015905078A AU2015905078A0 (en) 2015-12-08 Methods and Compositions For Treating Gastric Ulcers
PCT/AU2016/051205 WO2017096426A1 (en) 2015-12-08 2016-12-08 Methods and compositions for treating gastric ulcers

Publications (2)

Publication Number Publication Date
BR112018011552A2 true BR112018011552A2 (pt) 2018-11-27
BR112018011552B1 BR112018011552B1 (pt) 2024-08-20

Family

ID=

Also Published As

Publication number Publication date
ZA201804478B (en) 2020-12-23
CA3007446C (en) 2024-01-16
EP3386507A1 (en) 2018-10-17
HUE062857T2 (hu) 2023-12-28
SI3386507T1 (sl) 2023-10-30
EP3386507A4 (en) 2019-07-17
PL3386507T3 (pl) 2023-10-23
US11318123B2 (en) 2022-05-03
FI3386507T3 (fi) 2023-09-06
AU2016367707A1 (en) 2018-06-21
CA3007446A1 (en) 2017-06-15
PT3386507T (pt) 2023-09-11
WO2017096426A1 (en) 2017-06-15
HRP20231051T1 (hr) 2023-12-22
DK3386507T3 (da) 2023-09-18
NZ743099A (en) 2023-12-22
US20180133201A1 (en) 2018-05-17
HK1254232A1 (zh) 2019-07-12
AU2016367707B2 (en) 2022-01-27
ES2953929T3 (es) 2023-11-17
US20220202797A1 (en) 2022-06-30
EP3386507B1 (en) 2023-06-07
MX2018006921A (es) 2019-05-16

Similar Documents

Publication Publication Date Title
DOP2018000182A (es) Benzamidas sustituidas con 1,3–tiazol–2–ilo
BR112016014481A2 (pt) tratamento de câncer utilizando combinações de inibidores de erk e raf
PH12016500511A1 (en) Selective grp94 inhibitors and uses thereof
BR112017007072A2 (pt) compostos de triazolopiridina e métodos para o tratamento de fibrose cística
BR112015022588A2 (pt) composto, composição farmacêutica, e, método para tratamento de imunossupressão em um indivíduo
BR112016018604A2 (pt) Benzimidazol-2-aminas como inibidores de midh1
BR112013026494A2 (pt) composto, composição farmacêutica, método para tratar condição
AR083395A1 (es) Derivado peptidico nmu (neuromedina u) con elevado efecto anorectico
BR112014024793A2 (pt) método de inibição da ativação do complemento dependente de masp-3, e, composição farmacêutica.
BR112016007946A2 (pt) combinação farmacêutica, usos da mesma, de plinabulina e de composição, kits ou mistura e método para tratar e/ou prevenir câncer
BR112015022223A2 (pt) composições tópicas e métodos de tratamento de distúrbios tópicos
BR112016027041A8 (pt) combinações farmacêuticas para tratamento do câncer
DOP2016000253A (es) Nuevos compuestos
BR112017003186A2 (pt) composição farmacêutica para tratamento de cancer positivo para mutação em flt3, inibidor de flt3 mutante e usos dos mesmos
BR112015029240A2 (pt) composto, composição e método de evitar ou tratar inflamação associada com inflamassoma nrlp3 em um indivíduo
BR112016024020A8 (pt) composição farmacêutica
BR112017018198A2 (pt) inibição da atividade de olig2
BR112018014467A2 (pt) tecnologia de sinergismo fármaco-anticorpo para o tratamento de doenças
BR112015023214A8 (pt) composto, composição farmacêutica, e, uso de um composto ou composição farmacêutica
MX2018006921A (es) Métodos y composiciones para el tratamiento de úlceras gástricas.
AR089831A1 (es) Una composicion y un metodo para tratar sustratos
AR103636A1 (es) Métodos de tratamiento de neuralgia postherpética con una formulación tópica de un compuesto de espiro-oxindol
BR112017010028A2 (pt) ?métodos e composições para aumentar a pigmentação da pele?
AR101474A1 (es) Composición semioquímica inhibidora de la fijación de copepoditos de piojos de mar
WO2015200768A3 (en) Pharmacologic treatments of menière's disease

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: LUODA PHARMA LIMITED (IE)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 08/12/2016, OBSERVADAS AS CONDICOES LEGAIS